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Abstract
Background: The concept that cancer incidence and mortality are related to latitude was first suggested in
1930. Since then, there have been a plethora of studies addressing that connection. Studies of vitamin D have
demonstrated its anti-proliferative, anti-angiogenesis and differentiating properties which are all anti-
neoplastic. The relationship between prostate cancer and latitude has long been suspected. Prostate cells have
vitamin D receptors and enzymes for hydroxylation of vitamin D metabolites and enabling anti-carcinogenetic
effects. As a result of these findings, many ongoing studies are evaluating whether vitamin D deficiency
impacts prostate cancer risk. This review summarizes the last two years of published studies on this topic.
Methods: The search used Ovid/Medline, PubMed, CINAHL and Web of Science databases limited to
include clinical studies, English language, major journals and including articles from 2007 to the present.
Review of the abstracts produced the relevant studies, and the bibliographies of these articles led to other
sources not found in the search. Keywords: prostate cancer, risk, vitamin D and vitamin D deficiency.
Results: Five studies reviewed from the end of 2007 to the present were germane to the research topic. One
study was an observational study, one a prospective study and the remainder were case control studies from
much larger randomized controlled trials. Only one case reviewed the relationship between solar radiation
and prostate cancer risk and all the relationships were positive for low solar radiation and higher prostate
cancer risk. Three studies reviewed the relationship of serum levels of vitamin D and prostate cancer risk
relative to polymorphisms of the VDR and two found that low levels of serum vitamin D increase prostate
cancer risk, especially aggressive prostate cancer risk. One large study examining serum concentrations of only
one vitamin D metabolite found no association with PCa.
Conclusions: Vitamin D deficiency is a widespread health issue. There is an increased risk of prostate cancer
with low vitamin D levels.The risk is greater with more aggressive disease. Conflicting results regarding PCa
risk and VDR polymorphisms in light of low vitamin D levels, and it may be a one-time serum sample which
causes these discrepancies. There is an association between solar radiation and PCa risk, need to follow the
serum levels or solar exposure of patients much younger. Both metabolites need to be measured to understand
the impact on prostate cancer risk, especially since the data shows an increased risk with aggressive disease
with the one typically not measured. One serum sample does not provide information needed for
understanding the relationship between vitamin D and PCa. More prospective studies beginning at an earlier
age with more serum samples and solar radiation studies are needed in order to better understand the
relationship between prostate cancer and vitamin D.
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Abstract   
 
Background 
 The concept that cancer incidence and mortality are related to latitude was first suggested 
in 1930. Since then, there have been a plethora of studies addressing that connection.  
Studies of vitamin D have demonstrated its anti-proliferative, anti-angiogenesis and 
differentiating properties which are all anti-neoplastic. The relationship between prostate cancer 
and latitude has long been suspected. Prostate cells have vitamin D receptors and enzymes for 
hydroxylation of vitamin D metabolites and enabling anti-carcinogenetic effects. As a result of 
these findings, many ongoing studies are evaluating whether vitamin D deficiency impacts prostate 
cancer risk. This review summarizes the last two years of published studies on this topic.     
 
Methods 
 The search used Ovid/Medline, PubMed, CINAHL and Web of Science databases limited 
to include clinical studies, English language, major journals and including articles from 2007 to the 
present. Review of the abstracts produced the relevant studies, and the bibliographies of these 
articles led to other sources not found in the search. Keywords: prostate cancer, risk, vitamin D and 
vitamin D deficiency.  
 
Results 
 Five studies reviewed from the end of 2007 to the present were germane to the research 
topic. One study was an observational study, one a prospective study and the remainder were case 
control studies from much larger randomized controlled trials. Only one case reviewed the 
relationship between solar radiation and prostate cancer risk and all the relationships were positive 
for low solar radiation and higher prostate cancer risk. Three studies reviewed the relationship of 
serum levels of vitamin D and prostate cancer risk relative to polymorphisms of the VDR and two 
found that low levels of serum vitamin D increase prostate cancer risk, especially aggressive 
prostate cancer risk. One large study examining serum concentrations of only one vitamin D 
metabolite found no association with PCa. 
 
Conclusions  
 Vitamin D deficiency is a widespread health issue. There is an increased risk of prostate 
cancer with low vitamin D levels.The risk is greater with more aggressive disease. Conflicting 
results regarding PCa risk and VDR polymorphisms in light of low vitamin D levels, and it may be 
a one-time serum sample which causes these discrepancies. There is an association between solar 
radiation and PCa risk, need to follow the serum levels or solar exposure of patients much 
younger. Both metabolites need to be measured to understand the impact on prostate cancer risk, 
especially since the data shows an increased risk with aggressive disease with the one typically not 
measured. One serum sample does not provide information needed for understanding the 
relationship between vitamin D and PCa. More prospective studies beginning at an earlier age with 
more serum samples and solar radiation studies are needed in order to better understand the 
relationship between prostate cancer and vitamin D. 
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Does Vitamin D Deficiency Increase Prostate Cancer Risk? A Systematic 
Review of the Literature. 
 
 
 
INTRODUCTION 
 Prostate cancer is the most frequently diagnosed cancer in the country. It is the second 
leading cancer affecting males in the U.S.. There are approximately 220,000 new incidences and 
about 20,000 deaths each year.1 The five-year survival rate for localized or regional prostate cancer 
(PCa) is 100%, but if the cancer is metastasized at diagnosis, the rate drops to as low as 32%.2 
About 80% of PCa is diagnosed at the localized stage, and two-percent is diagnosed after spread 
just beyond the primary site or lymph nodes. 3  
 Prostate cancer will effect one in every six men in the U.S..3 This cancer primarily affects 
elderly men, with the median age at diagnosis, at 68 years (see Figure I).3 The risk of PCa 
increases with age, beginning at around 40. For the most part, the disease remains subclinical until 
around the age of 45, when the rate of diagnosis significantly increases (see Figure I). Fifty-seven 
percent of PCa diagnoses are in men 65 years and older, and roughly one third of those diagnosed 
are between the ages of 55-64.4, 5 In one study, autopsy prostate tissue samples revealed that there 
is an age-dependent increase in PCa.6  In this study, about 35% of deceased men from ages 60-69 
had PCa and 46% of men from the ages 70-81 had PCa, demonstrating the significant increase in 
the disease as men age, and the pervasiveness of the disease at the older ages. 
 Prostate cancer incidence rate varies significantly depending on race and ethnic background 
(see Figure II). Asian and Pacific Islanders have relatively low incidence rates and this is partially 
attributable to their fish diet.3 African American men are impacted at a substantially higher rate 
than white men, and their mortality rate is nearly double that of white men. (See Figure II).2, 3  
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 Prostate cancer impacts the lives of a great number of people each year with medical costs, 
worry regarding possible disease progression, medication side-effects, multiple medical office 
visits and frequent testing. Medical costs of PCa each year per patient amount to roughly 
$13,000.2, 3 As of 2006, there were approximately 2.2 million people living with a prostate cancer 
history, and, as the U.S. population ages, this number is expected to rise significantly in spite of 
recent trends downward (see Table II). 2, 3 
 
BACKGROUND 
 Prostate cancer is generally thought of as an insidious disease, developing many years 
subclinically. It typically is diagnosed at the point men are old enough for prostate exam screening, 
normally at age 50 unless if there is a family history or clinical signs. Sometimes it is never 
diagnosed and it becomes something men die with, rather than of, only being discovered during 
autopsy. Screening may be changing that scenario as it identifies up more and more disease. 
Screening consists of annual digital rectal exams (DRE) and prostate specific antigen (PSA) blood 
tests. Following initiation of the screening process, once the DRE notes asymmetric indurations or 
nodules or the PSA rises above 4ng, further investigation usually occurs with patients being 
referred to an urologist for a prostate biopsy. Some prostate cancer develops rapidly and signs 
appear clinically in a shorter time period.2  
 Prostate cancer, confined to the gland, is potentially curable, typically with resection of the 
gland. But within ten years of radiation therapy or radical prostactectomy, approximately 20-40% 
of PCa recurs, heralded by increasing PSA. Of these recurrent cases, a third will progress to 
clinical disease within eight years and treatment, at this point, is not well defined.4 
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  Extraprostatic cancers are treated with hormone or radiation therapy. Prostate growth and 
prostate cancer growth is androgen dependent and the treatment for advanced prostate cancer is 
androgen deprivation that results in prostate cell death. This treatment lasts a brief 14-20 months 
when the natural course of progression of prostate cancer leads to androgen independence. At that 
point, mean survival decreases to 19 months utilizing doxetaxel-based therapies.4 Side effects of 
prostate cancer treatment can include urinary incontinence, erectile dysfunction, sterility, proctitis, 
rectal bleeding, diarrhea, bleeding.7 This area of androgen-independent PCa is one of great 
resource expenditure with a large number of studies directed at treatment of aggressive or 
advanced prostate cancer.  
 The etiology of prostate cancer is not fully understood, but several risk factors have been 
identified, including obesity and dietary fat which some studies show it is a risk factor while others 
do not.2, 8, 9 Some studies indicate red meat increases prostate cancer risk.10 Research investigating 
the relationship between diet and prostate cancer risk is ongoing.10  
   
VITAMIN D & PROSTATE CANCER 
 Vitamin D has been investigated for years as having a potential impact on cancer in 
general.4 Schwartz et al noted in 1990, that the major risk factors for prostate cancer include: older 
age, black race and residence at northern latitudes.11 All of these risk factors have in common the 
reduced ability to synthesize vitamin D. In 1992, they printed a cartographic analysis which 
showed that the U.S. country-wide mortality rates for prostate cancer among white men, were 
correlated inversely with ultraviolet radiation, the major source of vitamin D (also see Figure III).11 
Schwartz also found that although levels of 25(OH)D were lower at higher latitudes, the levels of 
the active form of vitamin D, 1α,25(OH)2D, remained the same. Schwartz and his group proposed 
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that the reason for this was that the prostate produced its own active form of vitamin D in spite of 
levels of 25(OH)D .4  
 Prostate cells and PCa cells have vitamin D receptors (VDR) in the nucleus that have a 
high affinity for the 1,25(OH)2D form of vitamin D. These receptors initiate “pleotropic anticancer 
effects” on normal and PCa cells inhibiting cell proliferation, invasion, migration and metastasis.4 
They also inhibit cells that promote cell differentiation and angiogenesis.10 With the recognition 
that vitamin D has protective qualities, the possibility of using vitamin D for preventing prostate 
cancer was introduced. Since then, several studies have addressed the etiology of prostate cancer 
and the vitamin D hypothesis.11 
 
VITAMIN D METABOLITE SYNTHESIS 
 Vitamin D is a fat-soluble prohormone that plays an active role in bone health,  
 neuromuscular modulation, immune modulation and anti-inflammatory activity. Vitamin D is 
essential for calcium absorption in the intestine and for maintaining serum and phosphate 
concentrations for normal cell functioning and the maintenance of bone health. Not only is it 
important for bone mineralization, but also it serves roles in modulating neuromuscular and 
immune functions and in regulating inflammation.12  A key component in our immune system, T-
cells have a vitamin D receptor which, when filled, modulates T-cell activity.13  
 Approximately 90% of vitamin D is produced endogenously from the absorption of UVB 
in the skin, and the remaining 10% is absorbed from the intestine.14 Vitamin D is available in fatty 
fish, eggs and fortified dairy products. Vitamin D levels also can be supplemented with vitamin D 
or multivitamin pills.14   
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Vitamin D must go through two hydroxylations in the body before it is transformed to its 
active form.14 Synthesis of vitamin D metabolites begins in the skin with the production of D3 
(cholecalciferol) after the 7-dehydrocholesterol in the skin is exposed to ultraviolet radiation.4, 14 
Cholecalciferol is then hydroxylated in the liver to 25-hydroxyvitamin D (25(OH)D) or  calcidiol.  
The second hydroxylation occurs principally in the kidney resulting in bioactive vitamin D, 1α,25-
dihydroxyvitamin D (1,25(OH)2D or calcitriol). Organs other than the liver and the kidneys that 
also hydroxylize vitamin D into 1,25(OH)2D include the colon, breasts and the prostate.12 
 Influences that can decrease the absorption of UVB in the skin include age, skin 
pigmentation, sunscreen usage, latitude of residence, season and time of day.12 The enzyme that is 
necessary for the hydroxylization of vitamin D in the skin, is diminished in elderly people due to 
the age-related reduced production of the enzyme responsible for hydroxylation. This effectively 
decreases the amount of vitamin D hydroxylized. A 70 year-old person makes about 25% of the 
cholecalciferol made by a 20-year old.12  Skin color also impacts the amount of vitamin D 
produced. People with darker skin have more melanin which protects the skin from UV absorption, 
so they need extended exposure in order to gain the same benefit from absorption that lighter 
skinned people obtain. The latitude, season and time of day also impact the absorption of UVB 
into the skin as these conditions all cause an oblique angle for the sun’s rays, thereby increasing 
the distance that it travels through the ozone before being absorbed.12 Hence, latitudes further from 
the equator decrease the body’s ability to synthesize vitamin D. UVB absorption in winter months 
can be reduced as much as 80%-100%, again depending on the latitude and hours of the day due to 
the oblique angle of the suns rays.12 
 Vitamin D absorption into the serum is also affected by gastrointestinal, parathyroid, 
hepatic and renal diseases. These diseases impact the absorption of vitamin D and the conversion 
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of vitamin D into its active form. Additionally, since vitamin D is a fat soluble vitamin, it is stored 
in the fat of obese people and not maintained in the serum which can lead to a vitamin D 
deficiency in this population.14  
 Vitamin D deficiency is widespread in the United States. Data from the National Health 
and Nutrition Examination Survey (NHANES) demonstrated that a large proportion of men had a 
suboptimal vitamin D level.15 The study found that this especially was prevalent during winter and 
spring months with a 33% deficiency and with a 66% insufficiency. 15 
 Currently considered the best indicator of vitamin D levels in the body, is the serum 
concentration of 25(OH)D, which reflects both cutaneous production and dietary absorption.14 One 
reason why 25(OH)D is considered a good indicator of serum vitamin D, is because of its 
relatively long half-life of 15 days versus 1-α,25(OH)2D at only four hours.12 Serum 
concentrations are tightly controlled by parathyroid hormone, calcium and phosphate. Calcitriol is 
also produced locally to maintain levels in the body when a 25(OH)D deficiency exists, which 
means that calcitriol levels only fluctuate in the presence of a severe 25(OH)D deficiency. Serum 
25(OH)D is limited in its value as a measure of total body stores however, since it can only 
indicate serum levels and not the levels stored in other body tissues (see Figure IV). 
 Recommendations for daily intake of vitamin D are listed on the NIH Office of Dietary 
Supplement’s website, but, in spite of these recommendations, vitamin D deficiency is widespread 
in the U.S., especially in white and Black males. NHANES I found serum 25(OH)D at these 
levels:15 
• 1-9%    <11 ng/mL  (<27.5 nmol/L) 
• 8-36%   <20 ng/mL  (<50 nmol/L) 
• 50-78% <30 ng/mL  (<75 nmol/L).14 
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 Generally < 30 ng/mL is considered by health experts to be inadequate.14 Roughly 50-78% of the 
NHANES I participants were vitamin D deficient. See Table III for details regarding 
recommendations for healthy levels of vitamin D. 
  
VITAMIN D AND PROSTATE CANCER 
 Prostate cells and prostate cancer cells have receptors with a high affinity for the hormonal 
vitamin D form, 1-α,25(OH)2D. These receptors are referred to as vitamin D receptors (VDR).  
The the vitamin D metabolite 1-α,25(OH)2D is the one that has pleiotrophic anticancer effects on 
normal and cancerous prostate cells which have been demonstrated in numerous studies.4 The 
metabolite interaction with the VDR facilitates apoptosis and inhibition of cell proliferation, 
invasion, migration, metastasis and tumor angiogenesis. Vitamin D maintains the normal 
phenotype of prostatic cells through the differentiation of those cells. 
 Throughout the years, there have been a myriad of studies surrounding this topic. Some 
examined at the relationship between vitamin D serum levels and prostate cancer risk. Others tried 
to associate it with solar exposure, a vitamin D surrogate, with PCa risk, and still other researchers 
looked at vitamin D intake and PCa risk.10 A systematic review on the topic estimated that 42% of 
PCa risk may be genetic.10 The review summarized that the relationship between the genetic 
factors and the environment are complicated and more, larger interdisciplinary epidemiological 
studies are needed.10  
  Indications are that the vitamin D receptor (VDR) has a significant impact in the course of 
the disease, and it is for this reason tests are ongoing which use vitamin D in the treatment regimen 
for advanced cancer.4 This topic continues to interest the research community as they question if 
vitamin D deficiency increases prostate cancer risk. In the last year-and-a-half, one hundred 
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articles have been published on the topic of prostate cancer and vitamin D (MEDLINE search). If 
vitamin D deficiency can be managed through either UVB exposure or vitamin D supplementation 
to reduce prostate cancer incidence, then this public health issue could make a turnaround in terms 
of quality of life and cost of health care. To date, studies continue to show conflicting results with 
regard to the vitamin D association, but in spite of this, a systematic review of the epidemiological 
literature through much of 2008, concluded that the association between vitamin D and PCa risk is 
conclusive whether that association is through UVB or endogenous deficiency.4, 10 Since this topic 
gives rise to conflicting conclusions within the research world, this paper evaluates the results and 
the quality of the studies in the past two years to determine if there could be definitive conclusions 
regarding the question of whether vitamin D deficiency increases prostate cancer risk.  
  
METHODS 
 The thorough literature review used medical databases including Ovid/Medline, PubMed, 
CINAHL and Web of Science. The criteria limited articles to clinical studies, English language, 
major journals articles published from 2007 to the present. The review process included reading all 
the abstracts for relevancy and then reading the bibliographies from these articles to determine if 
there were any missing studies. The included articles in this study are listed in Table I. Keywords: 
prostate cancer, prostate cancer risk, risk, vitamin D and vitamin D deficiency.  
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RESULTS  
 
 Table I summarizes all the studies and their findings. Only one case reviewed the 
relationship between solar radiation and prostate cancer risk and all the relationships were positive 
for low solar radiation and higher prostate cancer risk. 20 Three studies reviewed the relationship of 
serum levels of vitamin D and prostate cancer risk relative to polymorphisms of the VDR and two 
found that low levels of serum vitamin D increase prostate cancer risk, especially aggressive 
prostate cancer risk.15, 16, 18 One large study examining serum concentrations of only one vitamin D 
metabolite found no association with PCa.17 Descriptions of these studies and their findings are 
found in this section, and a discussion of the merits of these cases and their findings are found in 
the following section. 
 The John et al study published in 2007 study was a nested case study from the National 
Health and Nutrition Examination Survey I Epidemiologic Follow-up Study (NHEFS). 20 This 
study cohort included 14,407 people 25-74 years of age in the (National Health and Nutrition 
Examination Survey) NHANES I in 1971-75. Of this group, there were 5,811 male participants 
from 55- 77 years of age of whom 306 were lost to follow-up (5.3%). In the follow-up study, 
researchers examined prostate cancer risk with early-life adult residential sun exposure and adult 
sun exposures that were assessed through self-report and a physician report and a dermatologic 
exam. Of the 5,811 total male participants, there were 249 who were diagnosed or deceased from 
PCa during the follow-up period which lasted from 1982-1992. Of these 249, there were 161 white 
cases selected. In NHEFS, there were 3,367 non-Hispanic men without prostate cancer for whom 
sun exposure information was available to researchers. 20 
 In John et al solar radiation in the state of birth was used as a measure of early-life sun 
exposure. Interviews with patients allowed them to determine solar exposure relative to the 
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residence length, to workplace exposure or to recreational exposure. They used Cox proportional 
regression modeling to estimate the relative risk of prostate cancer with 95% confidence intervals, 
which they age-adjusted. Only age needed to be adjusted because previous experience with the 
NHANES I study demonstrated no confounding relative to PCa by family history, fat or calcium 
intake. 20      
 Researchers looked at whether the vitamin D was more influential on early-state disease 
versus advanced by analyzing the combined PCa cases of those that were nonfatal verses fatal. 
They also stratified results for non-fatal and fatal cases to see the relationship with each type of 
PCa. They concluded that there was a significant reduction in PCa risk of fatal prostate cancer with 
both early-life and adult residence in an area with high solar radiation. 20     
 John et al found significant inverse associations between PCa incidence and men born in 
areas of high solar radiation with a 48% lower risk of PCa (RR 0.52); 95% CI, 0.32-0.8. They 
postulated a possible reason for this early-life association may lie in the development of the 
neonatal prostate because it expresses VDR receptors. Early life-exposure of rats with high 1-
α,25(OH)2D results in changes of the cellular composition of the prostate, from highly epithelial, 
to more stromal.19 Since epithelial cells are the targets for oncogenesis, researchers proposed that 
this may be a possible way in which early-life exposure to vitamin D can reduce prostate cancer 
risk. 21    
 John also concluded that people who live in an area of high residential solar radiation 
associates with reduced PCa risk (RR 0.59) 95% CI, 0.39- 0.88. With the data bifurcated, the study 
revealed that the state of high solar radiation and frequent solar exposures as an adult, produces a 
significant reduction for total PCa (RR 0.66) 95% CI, 0.47-0.93. The relationship between adult 
exposure and reduced risk especially holds true for fatal PCa (RR 0.34) 95% CI, 0.18-0.66. 20 
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 Study researchers concluded that their results were consistent with other studies that 
showed 1-α,25(OH)2D inhibits PCa cell invasion and metastasis. They commented that these 
findings illustrate the need for additional studies to distinguish effects of early-sun exposure and 
the impact on advanced/fatal prostate cancer.20   
 The Li study et al was a nested case-control study of the Physician’s Health Study (PHS) 
which was a randomized, double-blinded and placebo controlled trial of aspirin and β-carotene 
with 22,071 healthy male physicians in the U.S.. The study began in1982 with follow-up complete 
through the year 2000; the aspirin arm was terminated in 1987 due to the positive effects on 
cardiovascular health. Blood samples of 14, 916 men were drawn before randomization between 
the months of September and November, and it was from this baseline blood draw that study 
participants were selected.  There were 1,066 men who developed PCa between the study initiation 
in 1982, and the end of the follow-up period in 2000. Due to financial constraints, only baseline 
plasma concentrations of 25(OH)D and 1-α,25(OH)2D of 492 patients and 664 controls were 
measured along with DNA extraction. Cases were matched with three to four controls by age and 
smoking status. The final count evaluated 461 cases, matched to 471 controls, to discover the 
association between plasma vitamin D metabolites and VDR polymorphisms relative to PCa risk. 
They also checked to determine whether the interaction of the aspirin and the β-carotene modified 
the interaction of vitamin D and VDR polymorphisms and what their impact was on PCa risk.15 
 Li et al confirmed that vitamin D is a significant health issue, demonstrating that one-third 
of the study participants had a vitamin D deficiency, and that in the winter and spring, over half of 
the study participants were deficient. Over two-thirds had insufficiency in this crucial vitamin.15 
 The study results suggested that both vitamin D metabolites (25(OH)D and 1α,25(OH)2D) 
may play a role in PCa progression. They indicated that men with low levels of both of the vitamin 
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D metabolites, had an increased risk of aggressive PCa (advanced stage or high-grade), but not of 
non-aggressive prostate cancer. The authors reason that there has been inconsistency in other 
studies because those studies did not separate aggressive prostate cancer out from total PCa 
generally. Since the etiology of advanced PCa is different than the less aggressive form, these 
studies miss important data.15   
 The study examined the VDR polymorphisms that may be influenced by the vitamin D 
metabolite. Li et al found that vitamin D interacts with the VDR FokI polymorphism and modifies 
PCa risk. Also, men with the less functional FokI ff genotype were more susceptible to PCa in 
presence of low 25(OH)D levels, and this susceptibility  translates into a two-fold increased PCa 
risk. Conversely, men with the FokI ff genotype and high levels of 25(OH)D had a reduced risk for 
total and aggressive PCa. In this study, the authors indicated that two other studies reported the 
opposite finding: an increased risk with this genotype in the presence of high sun exposure. In past 
studies the BsmI polymorphism had been indicated as having interactions with vitamin D 
metabolites, however, this was not supported in the Li study with the winter and spring 
timeframe.15    
 This study also refuted other studies conclusions that age differences related to either 
metabolite, were insignificant. They found that low plasma1-α,25(OH)2D levels and the risk of 
aggressive PCa was prevalent among older men or men with insufficient 25(OH)D levels. Their 
research also suggested that the depletion of 1-α-hydroxylase, which converts vitamin D to its 
active form, has a role in the development and progression of PCa. As mentioned earlier in this 
paper, it is known that the levels of this enzyme decreases with advancing age. It was determined 
that low 25(OH)D did not impact 1,25(OH) 2D status with increased 1-α-hydroxylase activity, and 
this finding was attributed to the possibility that there may not be a correlation between the two 
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metabolites in samples collected in the winter and spring timeframe. With a lower 1-α-hydroxylase 
activity and low 25(OH)D status, this predisposes older men to a higher risk of PCa. The study 
suggested that low levels of both metabolites may be more indicative of vitamin D insufficiency 
than the current serum measurement of only 25(OH)D. Typically, the prostate produces its own 
1,25(OH) 2D  with a 25(OH)D deficiency, and it does so unless those levels are so low, it can no 
longer maintain 1,25(OH) 2D levels due to the lack of substrates. Since it is this active form of the 
metabolite that has the anticancer activity, they propose that a profound deficiency has the most 
impact on PCa risk.15  
 The Travis et al study, published in April 2009, found no significant association between 
concentrations of 25(OH)D and overall risk for PCa. This multicountry (7) nested-case control 
study was selected from the European Prospective Investigation into Cancer and Nutrition (EPIC). 
Blood samples from 139,209 men (91% of the 153,457 EPIC total) were provided before 
randomization. Travis et al used the identified 652 prostate cancer patients from the larger study 
and matched them with 752 controls, with a mean follow-up period of 4.1 years. Matching criteria 
for cases and controls included study center, age at enrollment (+/- 6 months), time of day of blood 
collection (+/-1 hour) and time of blood draw and last consumption of food or drink (<3, 3-6, >6 
hours).18 
  Travis examined the relationship between pre-diagnostic serum concentrations of 
25(OH)D and risk of PCa from EPIC prostate cancer cases and matched controls. They also 
evaluated the associations by stage and grade of the disease. Serum concentrations of 25(OH)D 
were assayed in the same batch, for both the cases and controls, with specimens blinded to the lab 
personnel.18 
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 Statistical analysis, with a weighted version of the paired-sample t test, evaluated 
differences between cases and controls in age, height, weight, body mass index and serum 
concentration of vitamin D. Data were then compared using conditional logistic regression models 
to calculate the odds ratios. The month of serum sample draw was evaluated to determine the 
influence on vitamin D concentrations. This was done using a mathematical model. Likelihood 
ratio-chi squared tests compared local and advanced prostate cancer with the trends in PCa risk and 
the logs of 25(OH)D concentration. They evaluated the risks relative to concentrations of vitamin 
D and calcium intake.18 
 Travis et al found no significant association between 25(OH)D and risk of prostate cancer 
(highest vs. lowest quintile: odds ratio 1.28, 95% confidence interval: 0.88, 1.88). They did 
acknowledge a significant variation in concentrations, which varied by month of collection and by 
country of recruitment. A subgroup analysis did not show a significant difference with regard to 
cancer stage or grade, age at diagnosis, body mass index, time from blood collection to diagnosis 
or calcium intake.18 
 After they standardized for month of collection, they found that men from ages 50-54 had 
vitamin D concentrations that were 12.5 nmol/L higher (P=.0.001) than men older than 70 years of 
age. This affirmed other studies’ findings indicating that vitamin D levels decrease with increasing 
age. Additionally they showed borderline significant association for men diagnosed before age 60 
(P for trend = 0.046). There was no difference noted between serum 25(OH)D and risk of PCa 
between men with an early (<4 years) versus a later (≥ 4 years) diagnosis.18  
 Travis also concluded that there was no association between 25(OH)D and PCa risk and 
calcium intake. It did not find an association between vitamin D deficiency and risk for men with a 
high (≥ 1,200 mg/day) or low (< 1,200 mg/day) intake of calcium. They found that high levels 
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calcium may increase risk of PCa, which was possibly attributable to reducing the amount of 
1,25(OH)2D synthesized from the suppression of  parathyroid hormone by the calcium level.18  
 The study focus of Mikhak et al was on VDR gene polymorphisms and haplotypes and 
their interaction with vitamin D metabolites and PCa risk. The study was a nested-case control 
study in the Health Professionals Follow-up Study. That study started in 1986 with 51,529 healthy 
U.S. male health professionals. Three separate blood sample draws taken at three different times 
between 1986 and 2000, revealed a total of 704 PCa cases. Researchers drew one blood sample 
from each patient, which was measured for levels of both vitamin D metabolites (25(OH)D and 
1,2(OH)2D) and for VDR genotyping.16 
 Mikhak concluded that VDR polymorphisms in BsmI and FokI are unlikely to be major 
determinants of PCa risk. They also did not find ff genotype to be associated with increased risk of 
aggressive PCa. Unlike previous studies, they did not observe an association between Cdx2 and 
the GATA3 SNP, which is a G to A substitution. Only with aggressive PCa, did not find an 
association between haplotypes, globally or with the individual Cdx2, Fok1 and Bsm1 common 
haplotypes and a risk of all PCa subtypes. They found a lower susceptibility to PCa with 
haplotypes A-f-b and A-F-B. They found that carriers of the variant Cdx2 A allele, who were low 
in plasma 25(OH)D, had lower risk of total, aggressive and poorly differentiated PCa. Also, those 
carriers of the Cdx2 A allele with 1,25(OH) 2D deficiency had risks of aggressive and poorly 
differentiated prostate cancer more than non-carriers. They did note that the FokI SNP might lead 
to a reduction in both aggressive and poorly differentiated PCa risks in individuals with only one 
copy of the of the FokI f allele, who were deficient in 1,25(OH) 2D. Carriers with the FF genotype 
who were deficient in 1,25(OH) 2D had an increased risk of total, aggressive and poorly 
differentiated cancers.16 
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 The authors found a suggested inverse linear relationship between 25(OH)D and advanced 
PCa risk. Men with plasma 25(OH)D deficiency were at a lower risk for total and poorly 
differentiated PCa. They were surprised to find that men with low 25(OH)D had a decreased PCa 
risk. They conjectured that this could be incidental or more likely due to a hormonal response of 
the parathyroid gland, stimulating additional enzymes to maintain plasma 1,25(OH) 2D at normal 
levels.16 
 The Ahn et al 2009 study looked at the association of 48 SNPs in four vitamin D 
metabolizing genes, using 749 PCa cases and 781 controls from the Prostate, Lung, Colorectal and 
Ovarian Cancer Screening Trial (PLCO). This randomized-controlled multicenter trial, of 
approximately 150,000 U.S. men and women, was designed to evaluate screening mechanisms for 
the early detection of the enumerated cancers. Enrollment started in 1993 and ended in 2001. Male 
study participants were enrolled in the National Cancer Institute Cancer Genetic Markers of 
Susceptibility (CGEMS) investigation of SNPS and prostate cancer risk. In this screening arm, 
there were 38,350 randomized men. Non-hispanic men with no prior history of prostate cancer 
were selected for cases and controls. Before October 1, 2003, study participants filled out a 
questionnaire and gave blood for the Prostate Specific Antigen test (PSA) and vitamin D serum 
levels. From this group, prostate cancer cases were detected, the tumors staged and clinical state 
determined. After eliminating the cases diagnosed within the first year due to the potential impact 
of the subclinical cancer on serum vitamin D, the initial 1,172 cases were whittled to 749 cases and 
781controls.17 
 CGEMS also examined the significant effects of SNPs associated with prostate cancer in 
PLCO and in four other replication studies totaling 4,020 cases and 4,028 controls (American 
Cancer Society Cancer Prevention Study II, 1790/1797; the Health Professionals Follow-Up Study, 
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619/620; the CeRePP French Prostate Case-Control Study, 671/671; and the Alpha-Toceopherol, 
Beta-Carotene Cancer Prevention Study, 940/940). They genotyped data in 212 tag SNPS in 12 
genes in PLCO prostate cancer cases and controls and the CGEMS cases and controls; this was a 
genome-wide association study. Blinded lab personal completed a vitamin D assay from non-
fasting cases and controls. Ahn et al claim this was the first large scale evaluation of both serum 
vitamin D status and candidate genes in the vitamin D pathway in relation to prostate cancer.17  
 The study found genetic variation in genes related to vitamin D metabolism and serum 
concentrations. After multivariate modeling, only two SNPs with associations to serum 25(OH)D 
concentrations remained: rs2282679 and rs1155563. No other tag SNPs were associated with 
serum concentrations. None of previous tag SNPs, including two previously implicated VDR SNPs 
(BsmI and FokI), were strongly associated with prostate cancer risk. None of the 61 SNPs in the 
VDR were associated with prostate cancer risk (Cdx2,TaqI,ApaI). The association of serum 
vitamin D and the results were null for disease aggressiveness, age at diagnosis and family history 
of prostate cancer.17  
  Genetic variation in the vitamin D pathway and PCa risk were stratified by serum vitamin 
D concentrations. They found a significant association between VDR genetic variation and PCa 
risk in men in the lowest tertiles of serum concentrations. Individual SNP analysis showed 
significant associations in men in the lowest tertiles of vitamin D concentration with three tag 
SNPS in or near the 3’ untranslated region (UTR) of the VDR. And contrary to other studies, 
greater serum vitamin D concentration was related to increased risk of prostate cancer in A allele 
carriers.17  
 Haplotype analysis was consistent with the SNP-based analysis, and it indicated the 
greatest risk was in the carriers of the GGG haplotype (of the three VDR SNPs). The sliding 
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window haplotype analysis was based on 89 geneotyped SNPS in VDR in men with low vitamin D 
status, and the authors suggested that additional unmeasured risk variants around these SNPs may 
exist which may influence prostate cancer risk (rs11574143, rs757343, rs1544410).  This study 
claims that other genetic studies were limited to selected VDR RFLP SNPs and show inconsistent 
results.17  
 There was only a modest differential in season-standardized vitamin D concentrations by 
variants in GC, which is the major protein carrier of vitamin D in serum. SNPs in GC were related 
to serum vitamin D, however, these SNPs were not associated with total or aggressive prostate 
cancer risk. Ahn et al conclude, that men in the lowest tertile of serum 25(OH)D, have an 
increased risk with tag SNPS in the 3’ UTR of the VDR 17  
 
 
DISCUSSION 
 
John et al was the only study that attempted to evaluate subjects’ vitamin D exposure at a 
point both early in life and then later. In assembling the data, the researchers used physician 
impression, patient comments and patient occupational or recreational exposure to derive a value. 
Physicians simply rated their impression of sun exposure as unimpressive, moderate or 
considerable. Nowhere in the printed account is there an indication that the physicians were trained 
to make anything other than a subjective analysis. The dermatological exam suffers the same fate. 
In order for a study to be somewhat valid, the use of terminology has to be standardized from one 
evaluator to the next, and that is not the case here. 
 Additionally, all the years of exposure are derived from estimated exposure hours in the 
state of birth, the state of residence, occupation and recreational exposure. They accumulated these 
hours in person years in order to gain more statistical power in their data analysis. Since the solar 
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exposure is already based on estimates, these person years are built on those estimates, and hence, 
their conclusions are based on those estimates. The actual case numbers used to draw these 
conclusions in this study are actually fairly small compared to the person years. This is particularly 
evident with the conclusion the authors make relative to fatal prostate cancer risk reduced by 66% 
for people who were both born in a state with high solar radiation and who lived the longest in a 
state with high solar radiation. This conclusion is made with a case size of 12 men, however, this 
represents 22,162 person years.20 Table IV and Table V of this paper shows the results of this 
study indicating sun exposure in adulthood and the risk of fatal and nonfatal prostate cancer.  Note 
the sample sizes for the ‘significant’ findings are small: 25, 33, 55 and 12 and the confidence 
intervals wide. Having noted the issues with this study, though, it still is evident that there is an 
inverse association with solar exposure at many points in life.  Since the study is based on these 
broad assumptions relative to the exposures, the purpose of this study remains as associative and 
more comprehensive and better designed prospective studies are needed to ascertain at which 
points in life, solar exposure has the biggest impact on PCa development. 
 Generally, the Li et al study was a well designed nested case control study from a much 
larger randomized controlled study, the Physicians Health Study (PHS). There was an 18 year 
follow-up of patients which was 99% complete for which they obtained vital status on 100% of the 
participants. 15 They had 1,618 cases from a population of 14,916 from which they also carefully 
drew their controls matching the cases as closely as possible. They Table I in the Li et al indicates 
the cases and controls were fairly similar except for differences in their vitamin D levels.15  
 The Li study found significant associations between serum vitamin D metabolites and 
aggressive prostate cancer risk in patients of the second lowest quartile of 1-α,25(OH)2D levels. 
This result is puzzling, and the study authors do not try to explain this anomaly.15  
28 
 
 Li et al, like several other studies on this topic, only take one serum sample, which, in this 
case, was the baseline serum draw.15 This issue is addressed further in this section. 
 Additionally, seventy-five percent of the samples were drawn in the summer and fall time 
frame, which is the time of year serum levels of vitamin D are the highest. Li handles this issue by 
creating cutoffs for the season based on vitamin D levels in the controls. It is questionable whether 
this methodology can account for the huge number of samples taken on the season with the highest 
levels of the specific component being tested. 15    
 Interesting to note, Li et al conclude that the physicians in this study have higher overall 
vitamin D levels than participants in other studies on the topic. They attribute this possibly to their 
general overall better understanding of health issues.15 This may also be why there are few 
significant findings in this group; their vitamin D status is actually higher, so if there were a 
connection between vitamin D deficiency and PCa, it would be less pronounced in this select 
population. If the Li et al statement is true, one would expect their prostate cancer rate to be less 
than the general male population, but they do not address this anywhere in the study. 
 A major asset to Travis et al was that it was a very large prospective study with large case 
and matched control populations. Table 1 in the published account showed the only difference 
between the groups is that the control group was more physically active than the case group.18 
Interesting to note, is that mean concentration of 25(OH)D does not vary between the case and the 
control groups. The authors looked at the data from every angle imaginable, so they were able to 
evaluate many relationships. Since it was such a large study, this provided the study the statistical 
power for their analysis.18 
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 In the Travis study, P values were only significant with men less than 60 years of age in the 
lower third of 25(OH)D concentrations, but confidence intervals are wide and crossed one, making 
their only finding insignificant.18  
 Another issue in this study, was that the authors did not match controls to cases relative to 
the month of blood collection. They tried to diffuse this issue by standardizing the vitamin D levels 
before they analyzed the data. Standardizing the month of blood draw removes one of the main 
attributes confirmed by a litany of studies; vitamin D levels vary by season, and hence, by month. 
 Additionally, the follow-up period for this study was a mere 4.1 years median. Taking 10-
15 years to develop, PCa onset typically is insidious, and with only a 4.1 year window of time, this 
may not have been captured in this study. With such a short follow-up period, one cannot be 
certain whether subclinical prostate cancer was developing and consequently affecting the vitamin 
D levels in the body.18 
 They acknowledged that they did not look at 1,2(OH)2D specifically, which could be a 
potential limitation of the study since it is at this level, where vitamin D exerts its actions. This 
study also relied on a one serum draw for 25(OH)D levels. 18 This is discussed further in this 
section.  
Mikhak et al also is a well designed study. This was a nested case-control study from the 
much larger prospective Health Professions Follow-up Study with 51,529 US male health 
professionals. The study included men diagnosed with PCa between 1993-2000 and the follow-up 
period ranged from 17-21 years, and this follow-up is key in understanding the risk of prostate 
cancer.16  
Mikhak argued that both metabolites need to be measured in order to fully understand the 
body vitamin D levels, and this is apparent from other studies in which both metabolites were 
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measured and where the bioactive metabolite conferred a higher risk for PCa.  The one major 
issue, that Mikhak et al relies on one blood draw for serum levels; this point is discussed further in 
this section.16 
  The major issue with the Ahn study is that they also only took one serum sample; this is 
discussed later in this section. They also tried to adjust for seasonal variation in vitamin D 
collection between cases and controls by calculating a season-standardized vitamin D levels.17 
Again, since the serum levels fluctuate with the seasons, one would consider that season would be 
an important factor not to adjust.  
  The sample size in this study limited Ahn’s findings. With such small sample sizes, they 
were not able to make statistically supported conclusions relative to the any relationship with 
vitamin D. The authors concluded on only one finding: two SNPs were impacted by serum vitamin 
D.17 
 Ahn et al only measured 25(OH)D.17 Mikhak et al postulated that both metabolites may 
need to be measured to provide a more definitive indication of vitamin D status since there is such 
an inter-relationship when levels of calcidiol drop severely.16 Giovannucci argued that there may 
be a dose response relationship that may only be operative at lower limits of vitamin D.21 Mikhak 
speculated that there also is an increase in PCa risk with low 1-α,25(OH)2D (with the Cdx2 A) and 
no association with 25(OH)D since there would not be enough substrate or enough 1-α-
hydroxylase to convert the latter. 16 Ahn et al did note that there was an inverse linear relationship 
between 25(OH)D and advanced PCa risk. 17  
Many authors have hinted at the possibility that the effect of vitamin D may be more 
relevant for prostate cancer progression or the subgroup of aggressive prostate cancer. Most of the 
studies thus far have evaluated the relationships with total PCa and not specifically with the two 
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subgroups of indolent disease or aggressive disease. The possibility of aggressive disease having 
different risk factors was supported in part with the studies in this review. Li et al point out that 1-
α-hydroxylase plays a role in progressive PCa, especially since as men age, the amount of this 
enzyme used in the hydroxylation of 25(OH)D to 1-α,25(OH)2D decreases, and the protective 
effect no longer keeps the cancer contained.15 This is true with aggressive disease. Mikhak et al 
also supported this concept in their findings that, if one is a carrier of a Cdx2 A allele, and if both 
levels are low, there is an increase in the risk of aggressive disease. 16 
Other concerns regarding these studies center around the taking of the serum draw and the 
analysis of it. Serum measurements of vitamin D were drawn in each of the studies in this review 
except the John et al study. Mikhak, Li and the Travis studies all had only one serum measurement 
upon which to run their data comparisons. 15, 16,18 Although the article does not stipulate, Ahn et al 
appears to only have done an initial vitamin D assay upon PCa diagnosis for both the cases and the 
controls.17 With only one serum draw, each of these studies only captured a snapshot in time of 
serum levels for the metabolite they measured. Such a limited draw ignores the fact that these 
levels fluctuate. This small snapshot in time does not adequately explain the impact of vitamin D 
serum levels on the evolution of the disease. Yet, all of these studies (except John et al) in this 
review and other studies utilizing serum draws, draw conclusions on associations between PCa and 
vitamin D using one serum sample.  
The risk for prostate cancer may begin earlier in life and that these adult studies may not 
represent a relevant time period. Giovannucci notes that prostate cancer likely begins in a person’s 
30’s, because of the presence of microscopic neoplastic lesions present in the prostate by that 
time.21 The activity of 1-α-hydroxylase decreases with prostate cancer, and this would have a 
direct impact on vitamin D levels. This means that the most useful period of time to evaluate 
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vitamin D levels would be early in the process. All of the studies reviewed here sampled serum in 
men older than 50 years. Serum levels of vitamin D need to be measured earlier in life to 
determine at what point vitamin D has the greatest impact on prostate cancer risk.  
 Another issue relative to serum measurement of vitamin D, is that in Travis, Mikhak and 
Ahn, controls were not matched to month of blood collection.16,17,18 They tried to diffuse this issue 
with standardization of the serum vitamin D levels by month of blood draw before they analyzed 
the data. Because of the significance of the monthly fluctuation in vitamin D levels, they may have 
not been able to assess the impact they had on PCa risk because of the standardization they 
performed in their analysis.  
 Mikhak et al postulated that both metabolites may need to be measured to provide a more 
definitive indication of vitamin D status.16 In a 2007 review, Giovannucci argued that there may be 
a dose response relationship that may only be operative at lower limits of vitamin D.21 Mikhak et 
al brought this up in their study noting that there was an inverse linear relationship between 
25(OH)D and advanced prostate cancer risk. 16 
 
 
CONCLUSION  
 All the studies in this review acknowledge, with good evidence, the presence of vitamin D 
deficiencies in the study participants demonstrating that this is a widespread health issue.  
 Four of the five studies conclude that there is an increased risk of prostate cancer with low 
serum vitamin D levels, and most indicate that this is more prevalent with the more aggressive 
disease. The only study not confirming the association has an extremely short follow-up period 
which may impact the findings they made as there may not have been enough time for PCa to 
develop in the population they studied.  
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 Evolving from this general discussion is the identification of the genetic components 
influenced by vitamin D levels. Studies continue to show conflicting results regarding PCa risk 
with the presence of VDR polymorphisms in light of low vitamin D levels. Mikhak et al 
demonstrated this issue with their finding that it was unlikely that BSMI and FOKI were unlikely 
determinants of PCa risk when previous studies, conducted by others, found that these 
polymorphisms were contributory to the increased risk.16 The fact that these studies conflict with 
previous studies, may demonstrate something is influencing the results: possibly variability of the 
timing in which the serum levels are being checked. It still is not known at what point vitamin D 
serum levels influence prostate cancer neogenesis. With the one-time serum draws concluding on 
vitamin D status, perhaps it is the variability itself that is possibly influencing the conflicting 
conclusions from study to study. 
 The associations drawn in the John et al study indicate that more information is needed 
regarding solar exposure and the PCa connection.20 The attempt to estimate solar exposure early in 
life is novel in this study, but this is only a beginning in an area of study that is really needed: 
prospective studies starting with ages much younger than 50 years.  Giovannuci and John et al 
postulated that prostate cancer genesis is probably in the third decade of life.20,21 With such an 
early genesis, it would be beneficial to follow the serum levels or solar exposure of patients much 
younger than these studies typically follow.  
Li et al discuss the need for measurement of both metabolites since it is in the presence of a 
deficiency of 1-α,25(OH)2D, that the risk of aggressive prostate cancer is increased.15 It appears 
that measurements of both metabolites provide a more comprehensive picture of the true severity 
of the deficiency because the status of 25(OH)D does not provide any information on the other 
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metabolite, 1-α,25(OH)2D.  It may be crucial to measure both metabolites to gain understanding 
the complex nature of the impact on prostate cancer risk.  
Finally, one serum sample does not seem to provide the information needed for 
determining the relationship between vitamin D and PCa. It does not seem reasonable that this 
one-time serum sample would have an impact on a disease that develops subclinically for so many 
years. Since this snapshot draw can happen anytime along the disease course, this one time draw 
cannot provide enough information to determine the impact of the deficiency on the disease 
course. With potentially a multitude of points in which serum vitamin D levels could relate to 
PCa’s course, each of the studies may be finding different points that may or may not influence 
PCa risk depending on when they draw that sample. The one measurement and the measurement of 
only one metabolite of serum vitamin D may be why study results continue to be in conflict.  
More prospective studies beginning at an earlier age with more serum samples and solar 
radiation studies are needed in order to better understand the relationship between prostate cancer 
and vitamin D. One conclusion is clear in these studies reviewed: low vitamin D levels have an 
impact on prostate cancer risk. 
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Table I. Does Vitamin D Deficiency Increase Prostate Cancer Risk? A Systematic Review of the Literature 
Source Study Type Population 
 
Ages Intervention Sample Size 
Years 
Follow
-up 
Validity Findings 
John et 
al20 
Nested 
case  
 
NHEFSAdults ages 25-74 
including 5,811; part of the 
NHANES Follow-up 
Study 
25-74 Blood samples 
serum 
25(OH)D 
161 cases  
3,367 non-
hispanic 
noncases 
(w/sun exp 
info) 
 
10 Lab work blinded.  PCa risk reduced for men 
born in, lived in or frequently 
exposed to solar radiation. 
Frequent adult exposure PCa 
risk reduction especially with 
fatal PCa. 
Li et al115 
 
Nested- 
case 
control  
 
Physicians Health Study 
14,916 men initially free 
dx ca 
 
40-84 Predx levels 
both vit D 
metabolites; 
DNA  
1,066 PCa 
cases  
1,618 ctls. 
18 NCC. RCT; Lab 
blinded. 
Well designed with 
excellent follow-up. 
PCa pts matched with 
controls were similar. 
All testing  
randomized. 
Vitamin D is major health 
issue. Low levels both 
metabolites had increased 
PCa risk for aggressive PCa. 
FokI ff genotype increases 
susceptibility for PCa in 
presence of low vitamin D. 
High 25(OH)D decreases PCa 
risk for total & aggressive 
disease. Low 1,25 vitamin D 
increased aggressive PCa risk 
with older men OR men with 
low 25(OH)D. Greatest risk 
of PCa risk with low levels 
both metabolites.  
Travis et 
al18 
Nested- 
case 
control 
Part of the EPIC with 
EPIC  Multicountry (10) to 
investigate relationships 
between diet, nutritional 
status, lifestyle 
&environmental factors &  
incidence of cancer & 
other chronic diseases.  
153,457 men of 520,000 
recruits; blood samples 
from 139,209 
35-73 Blood samples 
serum 
25(OH)D  
 
652 PCa 
cases; 
 752 ctls.  
4.1 NCC; from larger 
Prospective study; Lab 
blinded. Blood 
samples from 139,209 
men drawn pre-
randomization 
No significant association 
with 25(OH)D and PCa risk. 
Men 50-54 concentration 
levels 12.5nmol > men > 70  
yrs. No PCa risk with calcium 
intake, but high Ca+ increases 
PCa risk.  
Mikhak et 
al16 
Nested 
- case 
control 
 
 
Health Professions Follow-
up Study with 51,529 US 
male health professionals. 
Study included men dx 
with PCa between v1993-
2000. 
45-70 Blood samples 
to investigate 
the role of VDR 
Cdx2, Fok1 and 
Bsm1 gene 
polymorphisms 
and assoociated 
haplotypes & 
interaction with 
plasma vitamin 
D metabolites 
in relation to 
Pca risk 
 
684 PCa 
cases 
684 ctls. 
17-21 NCC from larger 
prospective study; lab 
blinded 
Cdx2 A allele carriers have 
lower risk aggressive & 
poorly differentiated PCa 
with low metabolites. Men 
with low 25(OH)D at risk for 
total & poorly differentiated 
PCa. Suggestion of inverse 
relationship between 
25(OH)D and advanced PCa 
risk.  
Ahn et 
al16, 16-18 
Nested-
case 
control 
PLCO Cancer Screening 
Trial of 155,000 men and 
women; (also part of 
CGEMS investigation of 
SNPs & PCa risk). 38,350 
men randomized to the 
screening arm  
≥ 50 Blood samples 
for serum; 
questionaire 
 
749 PCa 
cases 
781 ctls 
10 NCC; from RCT; lab 
blinded 
Men with lowest 25(OH)D 
have an increased PCa risk 
with tag SNPs in or near 3’ 
UTR if VDR. 
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Table II. Trend in incidence rates for Prostate Cancer for all Races16 
Trend Period 1975-1987 1987-1991 1991-1994 1994-2006 
Average percentage trend % 
 
+ 0.9 + 3.0 -0.6 -4.1 
 
 
Table III: Serum 25-Hydroxyvitamin D [25(OH)D] Concentrations and Health21 
ng/mL** nmol/L** Health status 
< 11 < 27.5 Vitamin D deficiency and rickets in infants and young 
children . 
< 10-15 < 25-37.5 Considered inadequate for bone and overall health in healthy 
individuals. 
≥ 30 ≥ 75 Proposed by some as desirable for overall health and disease 
prevention, although a recent government-sponsored expert 
panel concluded that insufficient data are available to support 
these higher levels. 
Consistently 
 > 200 
Consistently 
 > 500 
Considered potentially toxic, leading to hypercalcemia and 
hyperphosphatemia, although human data are limited. In an 
animal model, concentrations ≤400 ng/mL (≤1,000 nmol/L) 
demonstrated no toxicity. 
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Table IV. Sun exposure in adulthood and risk of fatal and nonfatal prostate cancer20  
 Nonfatal & Fatal  Nonfatal cases Fatal cases 
n Person-
yrs 
RR (95% CI)  n RR (95% CI)  n RR (95% CI) 
Ph
ys
ic
ia
n-
as
se
ss
ed
 Sun exposure Unimpressive 44 14,798 1.0  27 1.0  17 1.0 
Moderate 63 21,610 0.85 (0.58-1.25)  39 0.87 (0.54-1.43)  24 0.81- (0.44-1.51) 
Considerable 52 15,598 0.78 (0.52-1.17)  35 0.89 (0.53-1.47)  18 0.62 (0.32-1.20) 
           
Solar skin 
damage 
None 35 22,461 1.0  25 1.0  10 1..0 
Minimal 48 13,625 1.18 (0.76-1.84)  28 1.07 (0.62-1.86)  20 1.42 (0.66-3.04) 
Moderate to severe 78 16,387 1.13 (0.75-1.71)  49 1.16 (0.70-1.94)  29 1.13 (0.55-2.34) 
           
Se
lf-
re
po
rte
d 
Recreational 
sun exposure 
Never or rare 18 4,453 1.0  8 1.0  10 1.0 
Occasional 32 15,453 0.79 (0.44-1.4)  23 1.19 (0.53-2.66)  9 0.45 (0.18-1.12) 
Frequent 102 40,027 0.92 (0.55-1.52)  77 1.46 (0.70-3.02)  25 0.47 (0.23-0.99) 
           
Occupational 
sun exposure 
Never or rare 42 18,803 1.0  29 1.0  13 1.0 
Occasional 25 12,377 0.93 (0.57-1.53)  18 0.95 (.053-1.71)  7 0.88 (0.35-2.21) 
Frequent 86 28,750 1.05 (0.73-1.52)  62 1.11 (0.72-1.73)  24 0.89 (0.45-1.74) 
           
Occupational 
or recreational 
sun exposure 
Both, never, rare or 
occasional 
35 14,246 1.0  21 1.0  14 1.0 
One frequent 47 22,574 0.80 (0.52-1.24)  36 1.02 (0.60-1.75)  11 0.46 (0.21-1.02) 
Both frequent 70 23,058 1.05 (0.70-1.58)  51 1.28 (0.77-2.13)  19 0.70 0.35-1.40) 
*Confidence interval adjusted for age (continuous) 
 
Table V. Residential Sun Exposure Early Life and Adulthood Relative to Risk of Fatal and Nonfatal Prostate Cancer20 
 Nonfatal & Fatal   Nonfatal cases Fatal cases 
n Person-
yrs 
RR (95% CI) RR (95% CI)  n RR (95% CI)  n RR (95% CI) 
Solar radiation in 
state of birth 
Low 78 20,098 1.0 1.0*  44 1.0*  34 1.0* 
Medium 47 15,817 0.75 (0.52-1.07) 0.73 (0.48-1.09)  33 0.85 (0.52-1.40)  14 0.57 (0.28-1.14) 
High 25 12,773 0.52 (0.33-0.81) 0.49 (0.27-0.90)  20 0.59 (0.29-1.21)  5 0.31 (0.09-1.03) 
            
Solar radiation in 
state of longest 
residence 
Low 86 21,887 1.0 1.0*  43 1.0*  34 1.0* 
Medium 41 14,835 0.72 (0.50-1.05) 0.90 (0.58-1.38)  29 1.07 (0.63-1.81)  12 0.70 (0.32-1.50) 
High 33 14,591 0.59 (0.39-0.88) 0.80 (0.44-1.49)  25 1.02(0.49-2.13)  7 0.49 (0.15-1.59) 
 
            
Solar radiation in 
state of birth vs. 
state of longest 
residence 
Low vs low 82 22,210 1.0   47 1.0  35 1.0 
Low vs 
high 
8 2,055 0.87 (042-1.79)   4 0.78 (0.28-2.17)  4 1.00 (0.36-2.82) 
High vs low 
 
5 1,920 0.54 (0.22-1.33)   3 0.60 (0.19-1.93)  2 0.46 (0.11-1.93) 
High vs 
high 
55 22,162 0.66 (0.47-0.93)   43 0.89 (0.59-1.34)  12 0.34 0.18-0.66) 
* Adjusted for age and solar radiation in state of longest residence or in state of birth (continuous) 
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FIGURE I.  Prostate Cancer Age at Diagnosis3 
 
 
 
FIGURE II. Incidence and Death Rates of Prostate Cancer by Race per 100,0003 
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FIGURE III. Prostate Cancer Mortality by State22 
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Figure IV:  Vitamin D in Homeostasis19 
 
 
  
 
